ZetaGen Therapeutics: Funding, Investors & Team (Sep 2026)
Zetagen, a privately held, clinical-stage biopharmaceutical business established in 2015, is committed to fostering ground-breaking innovation in the management of metastatic bone malignancies and osteologic therapies. Our ZetaMetTM technology, which has been granted numerous patents, uses a novel molecular mechanism to stop cancer, reduce pain, and restore bone. In 2016, Zetagen obtained an exclusive licence from the State University of New York for the platform technology. The first human clinical trial for this innovative therapy, which utilises a drug-eluting implant technology, is scheduled to begin in Q4 2021. Further oncologic treatments for skeletal related events (SREs), such as ZetaMet FlowableTM and auxiliary osteologic treatments like ZetaFuseTM, ZetaSetTM, ZetaDentTM, and ZetaBaseTM, are also in the company's development in addition to ZetaMetTM.
ZetaGen Therapeutics has raised $19.4M across 2 funding rounds on record, the most recent a Series B of $9.8M announced in Aug 2023.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
ZetaGen Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2023.
ZetaGen Therapeutics Funding Rounds
ZetaGen Therapeutics raised $9.6M in an undisclosed round announced in Feb 2023.
6 months later, a Series B of $9.8M was announced in Aug 2023.
ZetaGen Therapeutics Founders and Leadership Team
Contact details for the ZetaGen Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →ZetaGen Therapeutics Funding Compared to Other Health Care Startups
ZetaGen Therapeutics' latest round of $9.8M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ZetaGen Therapeutics in Health Care and Syracuse
Companies Similar to ZetaGen Therapeutics
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
ZetaGen Therapeutics Funding FAQs
What does ZetaGen Therapeutics do?
Zetagen, a privately held, clinical-stage biopharmaceutical business established in 2015, is committed to fostering ground-breaking innovation in the management of metastatic bone malignancies and osteologic therapies. Our ZetaMetTM technology, which has been granted numerous patents, uses a novel molecular mechanism to stop cancer, reduce pain, and restore bone. In 2016, Zetagen obtained an exclusive licence from the State University of New York for the platform technology. The first human clinical trial for this innovative therapy, which utilises a drug-eluting implant technology, is scheduled to begin in Q4 2021. Further oncologic treatments for skeletal related events (SREs), such as ZetaMet FlowableTM and auxiliary osteologic treatments like ZetaFuseTM, ZetaSetTM, ZetaDentTM, and ZetaBaseTM, are also in the company's development in addition to ZetaMetTM.
How much funding has ZetaGen Therapeutics raised?
ZetaGen Therapeutics has raised $19.4M across 2 rounds on record. The most recent is a Series B of $9.8M announced in Aug 2023.
When did ZetaGen Therapeutics last raise funding?
ZetaGen Therapeutics' most recent funding round on record is a Series B of $9.8M, announced in Aug 2023.
Who founded ZetaGen Therapeutics?
FundedIQ lists Bryan Margulies (Founder), Nikhil Thakur (Founder) at ZetaGen Therapeutics.
Where is ZetaGen Therapeutics headquartered?
ZetaGen Therapeutics is based in Syracuse, New York, United States.
How many employees does ZetaGen Therapeutics have?
ZetaGen Therapeutics is in the 1-10 employee band.
How does ZetaGen Therapeutics' funding compare to other Health Care startups?
ZetaGen Therapeutics' latest round of $9.8M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's ZetaGen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ZetaGen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.